Clinical Trial

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This open-label extension study aims to evaluate the long-term safety and tolerability of weekly BMN 351 infusions, as well as to assess the effect of BMN 351 on physical function, in participants with DMD who participated in the 351-201 study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-01; most recent amendment 2026-07-23.
Trial Details
NCT Number NCT07573631
Lead Sponsor BioMarin Pharmaceutical
Conditions Duchenne Muscular Dystrophy (DMD)
Enrollment 18 participants
Start Date 2026-04-20
Primary Completion 2031-12 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-24